Most Read Articles
Roshini Claire Anthony, 3 days ago

Patients with mild hypertension who are at low risk for cardiovascular disease (CVD) do not appear to derive mortality or CVD benefit from antihypertensive treatments, raising questions on the need for treatment in this population, according to a recent study from England.

Pearl Toh, 5 days ago
A personalized computerized neurofeedback intervention for training attention and memory shows potential in cognitive training for healthy elderly men, who improved in cognitive performance after the training, although no significant improvements were seen in the overall study population.
4 days ago
The simple Atrial fibrillation (AF) Better Care (ABC) pathway holistically updates the integrated care for AF patients and helps reduce the risk of adverse outcomes such as all-cause mortality, stroke/major bleeding/cardiovascular death and hospitalization, according to a study.
Yesterday
Type 1 diabetes impairs cognitive functioning in children, and this effect is exacerbated by extreme glycaemic levels, according to a recent meta-analysis.

First-in-class CDK 4/6 inhibitor improves overall survival in advanced breast cancer patients

Dr. Joseph Delano Fule Robles
22 Oct 2018
Prof Massimo Cristofanilli. Photo from ESMO 2018.

Final analysis of results from the PALOMA-3 study showed improvement in overall survival (OS) with addition of cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib to fulvestrant in hormone receptorpositive, HER2-negative advanced breast cancer that has relapsed or progressed on hormonal therapy.

The final analysis of the prospective, randomized, phase III PALOMA-3 trial in 521 hormone receptorpositive, HER2-negative advanced breast cancer patients (median follow up, 44.8 months) showed that the median OS improved by 6.9 months with palbociclib plus fulvestrant vs placebo plus fulvestrant (34.9 months [95 percent confidence interval (CI), 28.8 to 40] vs 28 months [95 percent CI, 23.6 to 34.6]; p=0.043). [Cristofanilli M, et al, ESMO 2018, abstract LBA2_PR]

“This is the first report demonstrating that the absolute gain in [overall] survival is similar to the absolute gain in progression-free survival [PFS] in the whole population. This is very important to patients in terms of improving the chance of a long-term life in spite of advanced disease,” reported investigator Professor Massimo Cristofanilli of the Northwestern University, Feinberg School of Medicine, Chicago, US, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.

“The study was unpowered for OS so the data should be cautiously interpreted. Although the results strongly suggest that the PFS benefit may translate into OS benefit, the other trials conducted with CDK4/6 inhibitors will contribute to confirm the estimate of the OS benefit observed in this study,” commented discussant Dr Carmen Criscitiello of the European Institute of Oncology, Milan, Italy.  

Findings from the PALOMA-3 trial reported 2 years ago demonstrated that fulvestrant plus palbociclib was associated with significant and consistent improvement in PFS compared with fulvestrant plus placebo irrespective of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. [Lancet Oncol 2016;17:425-439]


Stay tuned for our full ESMO 2018 conference coverage

Read more:https://www.esmo.org/Press-Office/Press-Releases/PALOMA3-breast-cancer-palbociclib-fulvestrant-Cristofanilli

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

Patients with mild hypertension who are at low risk for cardiovascular disease (CVD) do not appear to derive mortality or CVD benefit from antihypertensive treatments, raising questions on the need for treatment in this population, according to a recent study from England.

Pearl Toh, 5 days ago
A personalized computerized neurofeedback intervention for training attention and memory shows potential in cognitive training for healthy elderly men, who improved in cognitive performance after the training, although no significant improvements were seen in the overall study population.
4 days ago
The simple Atrial fibrillation (AF) Better Care (ABC) pathway holistically updates the integrated care for AF patients and helps reduce the risk of adverse outcomes such as all-cause mortality, stroke/major bleeding/cardiovascular death and hospitalization, according to a study.
Yesterday
Type 1 diabetes impairs cognitive functioning in children, and this effect is exacerbated by extreme glycaemic levels, according to a recent meta-analysis.